文献速递骨质疏松与代谢性骨病

罗莫佐单抗对骨密度的影响取决于既往治疗:一项瑞士前瞻性多中心队列研究

The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland.
PubMed 文献 · Osteoporos Int · 2024-06-26

这项瑞士前瞻性多中心队列研究纳入99例高风险骨质疏松患者,测量罗莫佐单抗治疗12个月的骨密度变化。既往接受抗骨吸收治疗者骨密度反应减弱,且既往治疗时长与腰椎和全髋骨密度变化相关。

要点

  • 罗莫佐单抗治疗12个月使腰椎骨密度变化10.3%,全髋3.1%,股骨颈3.1%。
  • 既往抗骨吸收治疗减弱罗莫佐单抗的骨密度反应。
  • 既往抗骨吸收治疗时长与腰椎和全髋骨密度变化相关。

核心结论

  • 既往抗骨吸收治疗减弱了罗莫佐单抗的骨密度反应,且治疗时长与腰椎和全髋骨密度变化相关。

研究设计与样本

  • 这项前瞻性多中心队列研究纳入瑞士全国骨质疏松登记处99例患者(92名女性和7名男性,中位年龄71岁[65, 76]),于2021年1月至2023年12月入组,测量罗莫佐单抗治疗12个月的骨密度和骨转换标志物变化。

主要发现

  • 99例患者中22例无既往治疗,77例有既往治疗(包括23例有既往特立帕肽治疗史),既往抗骨吸收治疗累积中位时长6年[4, 11]。
  • 罗莫佐单抗治疗12个月后,腰椎骨密度变化为10.3%[7.5, 15.5],全髋为3.1%[1.1, 5.8],股骨颈为3.1%[0.5, 5.3]。
  • 既往治疗患者的骨密度反应显著较低,既往抗骨吸收治疗时长与腰椎和髋部骨密度增加呈负相关。
  • 全髋骨密度变化的其它预测因素包括基线髋部T值、体重指数和基线CTX水平,腰椎骨密度反应与基线腰椎T值、年龄和基线CTX水平相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This multicentre, prospective cohort study measured the effect of romosozumab for 12 months on bone mineral density, taking into account prior therapies. Prior antiresorptive therapy blunted the BMD response to romosozumab, and the duration was correlated with BMD changes at both the lumbar spine and total hip. INTRODUCTION: In Switzerland, romosozumab is administered to high-risk osteoporosis patients. Our study aimed to assess the effect of romosozumab on bone mineral density (BMD), taking into account prior therapies. METHODS: This multicentre, prospective cohort study measured the effect of romosozumab for 12 months in patients in a nationwide Swiss osteoporosis registry. BMD and bone turnover marker (P1NP and CTX) changes were measured and compared between pre-treated and treatment naïve patients. RESULTS: Ninety-nine patients (92 women and 7 men, median age 71 years [65, 76]) were enrolled from January 2021 to December 2023. Among them, 22 had no prior treatment before romosozumab, while 77 had previous therapy (including 23 with a history of prior teriparatide therapy), with a median duration of 6 years [4, 11] of cumulative antiresorptive treatment. Over 12 months, romosozumab led to BMD changes of 10.3% [7.5, 15.5] at the lumbar spine, 3.1% [1.1, 5.8] at the total hip and 3.1% [0.5, 5.3] at the femoral neck, indicating notable variability. Significantly lower BMD responses were observed in pre-treated patients, with the duration of prior antiresorptive therapy inversely associated with BMD increases at the lumbar spine and hip. Other predictors of BMD changes at the total hip included baseline T-scores at the hip, body mass index and baseline CTX level, while the BMD response at the lumbar spine was associated with the lumbar spine T-score at baseline, age and baseline CTX level. CONCLUSION: Prior antiresorptive therapy blunted the BMD response to romosozumab, and the duration was correlated with BMD changes at both the lumbar spine and total hip.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Everts-Graber J, Wenger M, Oser S, et al. The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland. Osteoporos Int. 2024. PMID: 38922397. doi:10.1007/s00198-024-07155-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。